United Therapeutics Corporation (UTHR) Earnings History
Elite Compounder28 years of earnings data (1998–2025) · 5-year EPS CAGR exceeds 18% — top-tier earnings quality
Loading earnings history...
United Therapeutics Corporation (UTHR) Earnings Overview
As of June 23, 2026, United Therapeutics Corporation (UTHR) reported trailing twelve-month net income of $1.29B, reflecting +13.1% year-over-year growth. The company earned $27.28 per diluted share over the past four quarters, with a net profit margin of 41.9%.
Looking at the long-term picture, UTHR's 5-year EPS compound annual growth rate (CAGR) stands at +19.3%, indicating exceptional earnings growth. The company achieved its highest annual net income of $1.33B in fiscal 2025, representing a new all-time high.
United Therapeutics Corporation maintains industry-leading profitability with a gross margin of 87.9%, operating margin of 47.7%, and net margin of 41.9%. This margin structure demonstrates strong pricing power and operational efficiency. View revenue history →
Compared to peers including IDYA (-$140M net income, -52.0% margin), RARE (-$609M net income, -85.4% margin), ACAD ($376M net income, 36.5% margin), UTHR has outperformed on profitability metrics. Compare UTHR vs IDYA →
UTHR Earnings vs Peers
Earnings metrics vs comparable public companies
UTHR Historical Earnings Data (1998–2025)
28 years| Fiscal Year | Net Income | YoY % | Operating Income | EPS (Diluted) | Net Margin | Op. Margin |
|---|---|---|---|---|---|---|
| 2025 | $1.33B | +11.7% | $1.52B | $27.86 | 41.9% | 47.7% |
| 2024 | $1.20B | +21.4% | $1.38B | $24.64 | 41.5% | 47.9% |
| 2023 | $985M | +35.4% | $1.18B | $19.81 | 42.3% | 50.9% |
| 2022 | $727M | +52.9% | $980M | $15.00 | 37.6% | 50.6% |
| 2021 | $476M | -7.6% | $556M | $10.06 | 28.2% | 33.0% |
| 2020 | $515M | +592.6% | $594M | $11.54 | 34.7% | 40.0% |
| 2019 | -$105M | -117.7% | -$188M | $-2.39 | -7.2% | -12.9% |
| 2018 | $589M | +41.0% | $805M | $13.39 | 36.2% | 49.5% |
| 2017 | $418M | -41.4% | $815M | $9.31 | 24.2% | 47.2% |
| 2016 | $714M | +9.5% | $1.06B | $15.25 | 44.6% | 66.4% |
| 2015 | $652M | +91.6% | $699M | $12.72 | 44.5% | 47.7% |
| 2014 | $340M | +94.8% | $539M | $6.28 | 26.4% | 41.8% |
| 2013 | $175M | -42.7% | $292M | $3.28 | 15.6% | 26.2% |
| 2012 | $304M | +39.7% | $422M | $5.71 | 33.2% | 46.0% |
| 2011 | $218M | +105.7% | $318M | $3.67 | 29.3% | 42.8% |
| 2010 | $106M | +444.2% | $164M | $1.78 | 17.5% | 27.2% |
| 2009 | $19M | +145.5% | $26M | $0.35 | 5.3% | 7.0% |
| 2008 | -$43M | -315.5% | -$82M | $-0.93 | -15.2% | -29.1% |
| 2007 | $20M | -73.2% | $6M | $0.44 | 9.4% | 3.0% |
| 2006 | $74M | +13.8% | $29M | $1.53 | 46.3% | 18.2% |
| 2005 | $65M | +320.8% | $43M | $1.29 | 56.1% | 37.0% |
| 2004 | $15M | +255.0% | $13M | $0.33 | 21.0% | 17.9% |
| 2003 | -$10M | +57.8% | -$12M | $-0.24 | -18.7% | -21.6% |
| 2002 | -$24M | +36.6% | -$18M | $-0.57 | -78.5% | -59.8% |
| 2001 | -$37M | +50.7% | -$47M | $-0.92 | -650.6% | -818.9% |
| 2000 | -$76M | -125.7% | -$82M | $-1.97 | -3689.6% | -3977.1% |
| 1999 | -$34M | -161.7% | -$35M | $-1.26 | -8375.0% | -8850.0% |
| 1998 | -$13M | - | -$13M | $-0.77 | -12800.0% | -13300.0% |
Download Data
Export UTHR earnings history in CSV or JSON format
Free sign-in required to download data
Full Stock Analysis
Deep dive into UTHR consensus models and risk factors.
Intrinsic Valuation
DCF models, multiple analysis, and analyst estimates.
Historical Returns
28+ years return with dividends reinvested.
DCA Calculator
See how regular investing compounds over time.
Peer Comparison
Compare growth, multiples, and margins vs sector.
UTHR — Frequently Asked Questions
Quick answers to the most common questions about buying UTHR stock.
What is UTHR earnings per share (EPS)?
UTHR trailing twelve-month (TTM) diluted EPS is $27.28, reflecting +13.1% year-over-year growth. The 5-year EPS CAGR is +19.3%. Complete EPS history from 1998 to 2025 is available in the table on this page.
What is United Therapeutics Corporation's net income?
United Therapeutics Corporation (UTHR) trailing twelve-month net income is $1.3B as of 2025. Earnings grew +13.1% year-over-year. United Therapeutics Corporation has been profitable for 6 consecutive years.
Is UTHR profitable?
Yes, UTHR is profitable with a TTM net income of $1.3B and a net profit margin of +41.9%. United Therapeutics Corporation has generated profits for 6 consecutive years.
What is UTHR's earnings growth rate?
UTHR compound annual EPS growth rates (CAGR): 1-Year: +13.1%, 3-Year: +22.9%, 5-Year: +19.3%, 10-Year: +8.2%. These figures measure the annualised rate of diluted EPS growth over each period, based on data from 1998 to 2025.
What are UTHR's profit margins?
United Therapeutics Corporation net profit margin is +41.9%, operating margin is +47.7%, and gross margin is +87.9%. Above-average net margins reflect strong pricing power and competitive moat. Return on Equity is +19.7%.
Is UTHR growing earnings?
UTHR is growing earnings steadily. YoY EPS growth of +13.1% is consistent with the 5-year CAGR of +19.3%. TTM net income is $1.3B.
What was UTHR's best earnings year?
United Therapeutics Corporation's highest annual net income on record is $1.3B, achieved in fiscal year 2025. Earnings history on this page spans 1998 to 2025 and includes all annual and quarterly figures.
What were UTHR's earnings last quarter?
UTHR's most recent reported quarter was Q1 2026. Net income was $275M with diluted EPS of $5.82. For a full breakdown of all quarters, see the quarterly earnings table on this page.